Finance Watch: Actuate Launches 15th Biopharma IPO In The US For 2024
Funding Comes Ahead Of Q1 Phase II Readout
Public Company Edition: Actuate Therapeutics grossed $22.4m in its first-time offering, while already-public companies recently tapped a variety of sources for funding. Arrowhead negotiated a credit facility for up to $500m and ANI sold $275m worth of notes, among other financings.
